Table 3.
Incidence of treatment-related adverse events with first-line immunotherapy regimens in NSCLC in phase III RCTs with positive OS results
| 1L approach | RCT | Investigational arm (versus platinum-based chemo) | G ≥3 TRAEs (%)a | Treatment discontinuation due to any TRAEs (%)a |
|---|---|---|---|---|
| Single-agent immunotherapy | KEYNOTE 024 | Pembrolizumab | 26.6% (versus 53.3%) | 7.1% (versus 10.7%) |
| KEYNOTE 042 | Pembrolizumab | 18% (versus 41%) | 9% (versus 9%) | |
| IMpower110 | Atezolizumab | 33.9% (versus 56.7%) | 6.3% (versus 16.3%) | |
| Empower Lung 01 | Cemiplimab | 14% (versus 39%) | 6% (versus 4%) | |
| Chemotherapy plus single-agent immunotherapy | KEYNOTE 189 | Pembrolizumab + platinum + pemetrexed | 67.2% (versus 65.8%) | 25.7% (versus 14.8%) |
| KEYNOTE 407 | Pembrolizumab + carboplatin + (nab)paclitaxel | 69.8% (versus 68.2%) | 25.5% (versus 12.8%) | |
| IMpower150 | Atezolizumab + bevacizumab + carboplatin+ paclitaxelb | 58.5% (versus 50%) | 32.6% (versus 24.9%) | |
| IMpower130 | Atezolizumab + carboplatin + nabpaclitaxel | 75% (versus 61%) | 26% (versus 22%) | |
| Double-agent immunotherapy | CheckMate 227 | Nivolumab + ipilimumab | 32.8% (versus 36%) | 18.1% (versus 9.1%) |
| Chemotherapy plus single-agent immunotherapy | CheckMate 9LA | Nivolumab + ipilimumab + two cycles of platinum-based chemotherapy | 47% (versus 38%) | 19% (versus 7%) |
| POSEIDON | Durvalumab + tremelimumab + platinum-based chemotherapy | NR | NR |
1L, first line; G, grade; NR, not reported; NSCLC, non-small-cell lung cancer; OS, overall survival; RCT, randomized, controlled trial; TRAE, treatment-related adverse event.
a
Versus comparator arm.
b
Comparator arm: atezolizumab + carboplatin + paclitaxel.